Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

satipharm

  • Home
  •  
  • satipharm



  • Most Read
  • Latest Comments
  • Cann Group strengthens position with variation agreement in medicinal cannabis sector
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Cann Group strengthens position with variation agreement in medicinal cannabis sector
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Cann Group strengthens position with variation agreement in medicinal cannabis sector
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Cann Group strengthens position with variation agreement in medicinal cannabis sector
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Cann Group strengthens position with variation agreement in medicinal cannabis sector
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
    • News

  • Melodiol moves to clear debt with $12m asset fire sale
    Melodiol moves to clear debt with $12m asset fire sale
    • News

  • Althea to make a splash in the US with new cannabis-based sodas
    Althea to make a splash in the US with new cannabis-based sodas
    • News

  • Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
    • News

  • Wellnex ventures into medicinal cannabis with it’s new Wellness Life brand
    Wellnex ventures into medicinal cannabis with it’s new Wellness Life brand
    • News

  • Cann Group strengthens position with variation agreement in medicinal cannabis sector
    • News

    Cann Group strengthens position with variation agreement in medicinal cannabis sector

    The medicinal cannabis industry in Australia has been rapidly gaining momentum, reaching an estimated value of approximately $245 million in 2022 and is projected to maintain a strong CAGR of 16.71% from 2023 to 2027. While the availability of cannabis for general use remains restricted in Australia, the nation continues to attract cannabis manufacturing companies

    Read More
    Public
  • Cann’d: clinical trials show no difference between cannabis capsules and placebo
    • News

    Cann’d: clinical trials show no difference between cannabis capsules and placebo

    Since the easing of regulatory red tape and wider societal acceptance of utilising cannabis for its medical properties, the medicinal cannabis industry has become an intense battleground as researchers have raced towards commercial products. In the case of Cann Group (ASX: CAN) though, they might have just triggered a land mine.  Undertaking any form of

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.